trial

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCTId NCT00539071
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 160 (actual)
Sponsored by Northwestern University
Primary completion 2012-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
160 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-03
Primary completion
2012-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Northwestern UniversityLead Sponsor
Ortho-McNeil Janssen Scientific Affairs, LLCCollaborator

Investigators

1
Herbert Y Meltzer, M.D.Principal Investigator

Sites

1 total
Nashville, United States

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE4
Primary Completion Date
2012-05
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Northwestern University
company
collaborator
Ortho-McNeil Janssen Scientific Affairs, LLC
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Herbert Y Meltzer, M.D.
person